These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 18056788)
61. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Rüttimann EB; Arnold M; Hillebrand JJ; Geary N; Langhans W Endocrinology; 2009 Mar; 150(3):1174-81. PubMed ID: 18948395 [TBL] [Abstract][Full Text] [Related]
62. Glucose-induced suppression of endogenous glucose production: dynamic response to differing glucose profiles. Vella A; Reed AS; Charkoudian N; Shah P; Basu R; Basu A; Joyner MJ; Rizza RA Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E25-30. PubMed ID: 12637258 [TBL] [Abstract][Full Text] [Related]
63. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721 [TBL] [Abstract][Full Text] [Related]
64. Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog. Edgerton DS; An Z; Johnson KM; Farmer T; Farmer B; Neal D; Cherrington AD Am J Physiol Endocrinol Metab; 2013 Jul; 305(1):E132-9. PubMed ID: 23673158 [TBL] [Abstract][Full Text] [Related]
65. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Carr RD; Larsen MO; Winzell MS; Jelic K; Lindgren O; Deacon CF; Ahrén B Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E779-84. PubMed ID: 18612044 [TBL] [Abstract][Full Text] [Related]
66. Insulin levels after portal and systemic insulin infusion differ in a dose-dependent fashion. De Vos P; De Haan BJ; Vegter D; Hillebrands JL; Strubbe JH; Bruggink JE; Van Schilfgaarde R Horm Metab Res; 1998 Dec; 30(12):721-5. PubMed ID: 9930629 [TBL] [Abstract][Full Text] [Related]
67. Insulin as a mediator of hepatic glucose uptake in the conscious dog. Cherrington AD; Williams PE; Abou-Mourad N; Lacy WW; Steiner KE; Liljenquist JE Am J Physiol; 1982 Feb; 242(2):E97-101. PubMed ID: 7039339 [TBL] [Abstract][Full Text] [Related]
68. Characterization of the portal signal during 24-h glucose delivery in unrestrained, conscious rats. Ogihara N; Kawamura W; Kasuga K; Hayashi Y; Arakawa H; Kikuchi M Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E932-40. PubMed ID: 14709421 [TBL] [Abstract][Full Text] [Related]
69. Portal serotonin infusion and glucose disposal in conscious dogs. Moore MC; Geho WB; Lautz M; Farmer B; Neal DW; Cherrington AD Diabetes; 2004 Jan; 53(1):14-20. PubMed ID: 14693692 [TBL] [Abstract][Full Text] [Related]
70. Evidence that the gastrointestinal tract is involved in glucose homeostasis. Alada AR; Oyebola DD Afr J Med Med Sci; 1996 Sep; 25(3):243-9. PubMed ID: 10457799 [TBL] [Abstract][Full Text] [Related]
71. Direct and indirect effects of insulin on hepatic glucose production in diabetic depancreatized dogs during euglycemia. Gupta N; Park E; Sandhu H; Goh T; Tchipashvili V; Giacca A J Endocrinol; 2006 Sep; 190(3):695-702. PubMed ID: 17003270 [TBL] [Abstract][Full Text] [Related]
72. Effects of portal free fatty acid elevation on insulin clearance and hepatic glucose flux. Yoshii H; Lam TK; Gupta N; Goh T; Haber CA; Uchino H; Kim TT; Chong VZ; Shah K; Fantus IG; Mari A; Kawamori R; Giacca A Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1089-97. PubMed ID: 16390863 [TBL] [Abstract][Full Text] [Related]
74. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels. Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873 [TBL] [Abstract][Full Text] [Related]
75. Differential effect of amino acid infusion route on net hepatic glucose uptake in the dog. Moore MC; Hsieh PS; Flakoll PJ; Neal DW; Cherrington AD Am J Physiol; 1999 Feb; 276(2):E295-302. PubMed ID: 9950789 [TBL] [Abstract][Full Text] [Related]
76. The effect of tolbutamide and hepatic extraction of insulin and glucagon and hepatic glucose output in anesthetized dogs. Ishida T; Chou MC; Lewis RM; Hartley CJ; Entman M; Field JB Endocrinology; 1981 Aug; 109(2):443-50. PubMed ID: 7018888 [TBL] [Abstract][Full Text] [Related]
77. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612 [TBL] [Abstract][Full Text] [Related]
78. Magnitude of negative arterial-portal glucose gradient alters net hepatic glucose balance in conscious dogs. Pagliassotti MJ; Myers SR; Moore MC; Neal DW; Cherrington AD Diabetes; 1991 Dec; 40(12):1659-68. PubMed ID: 1684554 [TBL] [Abstract][Full Text] [Related]
79. Role of brain prostanoids in glucagon-like peptide-1-induced central activation of sympatho-adrenomedullary outflow in rats. Arai J; Okada S; Yamaguchi-Shima N; Shimizu T; Sasaki T; Yorimitsu M; Wakiguchi H; Yokotani K Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):965-70. PubMed ID: 18505450 [TBL] [Abstract][Full Text] [Related]
80. Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog. Gustavson SM; Chu CA; Nishizawa M; Farmer B; Neal D; Yang Y; Donahue EP; Flakoll P; Cherrington AD Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E695-707. PubMed ID: 12626324 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]